4D Molecular Therapeutics, Inc. Net Income Loss

• 4D Molecular Therapeutics, Inc. showed an increase of +12.9% in Net Income Loss from 2024 to 2025.
• This data is from 4D Molecular Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), 4D Molecular Therapeutics, Inc.'s Net Income Loss has declined by 184.2%.
• Historical annual values: Fiscal year 2025: -$140.11 million | Fiscal year 2024: -$160.87 million | Fiscal year 2023: -$100.84 million | Fiscal year 2022: -$107.49 million | Fiscal year 2021: -$71.32 million | Fiscal year 2020: -$56.69 million | Fiscal year 2019: -$49.31 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026